Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BTLC, Ltd. 〉Platform_Antibody-Linked Nanomedicines

Platform_Antibody-Linked Nanomedicines

Platform_Antibody-Linked Nanomedicines

Active Targeting: Using Antibodies to Deliver Drugs to Specific Tissues.

Request for Collaboration
Overview
TLC is using antibodies and antibody fragments attached to lipid encapsulated drugs to develop more effective therapies in oncology. These antibody-linked nanomedicines actively target specific tissues using binding interactions between a specific antibody and a target antigen on the surface of a particular cell type. Compared with passively targeted therapies, these nanomedicines are better able to reach tissues farther from blood vessels and improve the biodistribution of the therapeutic payload. In addition, lipid-based antibody-linked nanomedicines can deliver a higher quantity of payload molecules compared to other actively targeted therapies like antibody-drug conjugates (ADCs). While ADC's are capable of delivering 3 to 4 molecules of payload for each linked antibody, TLC's nanomedicines are capable of delivering approximately 10,000 molecules with less than 100 antibodies. This approach is far more efficient and will likely translate into new treatments with higher efficacy. TLC's development of antibody-linked nanomedicines builds on past successes in improving the delivery of cytotoxic drugs for therapies in oncology.
Application
Active targeting to disease site.
Advantages:
  • Active targeting
  • Internalization of target liposome
People who like this also like
  • PHN014 (Acute ischemia stroke)PHN014 (Acute ischemia stroke)
  • Lead optimizationLead optimization
  • PHN033 (Diabetic Nephropathy treatment)PHN033 (Diabetic Nephropathy treatment)
  • Isoniazid without liver toxicityIsoniazid without liver toxicity
  • ELISAELISA
  • low-alcohol formulation (iLEF) platformlow-alcohol formulation (iLEF) platform
  • OB318- New drug for anti-liver cancerOB318- New drug for anti-liver cancer
  • NGS-SMSEQ®NGS-SMSEQ®
  • Lead discoveryLead discovery
  • SB04SB04